Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 2/20 | 0.60 |
| ▸ | ACE | P12821 | 2/20 | 0.60 |
| ▸ | CPA1 | P15085 | 1/20 | 0.60 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | ECE1 | P42892 | 1/20 | 0.52 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | APEX1 | P27695 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.37 |
| ▸ | CTH | P32929 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13668915 | 0.92 | MME (0.53) | MMEACECPA1ACE2ALDH1A1 | |
| SCHEMBL15981921 | 0.86 | MME (0.47) | MMEACECPA1ACE2ALDH1A1 | |
| SCHEMBL5404763 | 0.82 | ALDH1A1 (0.59) | MMEACECPA1ACE2ALDH1A1 | |
| SCHEMBL11206050 | 0.82 | ALDH1A1 (0.59) | MMEACECPA1ACE2ALDH1A1 | |
| SCHEMBL13330257 | 0.82 | MME (0.41) | MMEACECPA1ACE2ALDH1A1 | |
| SCHEMBL26774995 | 0.82 | MME (0.41) | MMEACECPA1ACE2ALDH1A1 | |
| SCHEMBL11206052 | 0.82 | ALDH1A1 (0.59) | MMEACECPA1ACE2ALDH1A1 | |
| SCHEMBL1642433 | 0.82 | ALDH1A1 (0.59) | MMEACECPA1ACE2ALDH1A1 | |
| SCHEMBL18932272 | 0.81 | — | — | |
| SCHEMBL605099 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12584924-B2 | Compositions and methods for diagnosing and treating chronic kidney disease | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2026-03-24 | — | — | US | claimed |
| US-11906510-B2 | Metabolic profiling by reverse-phase/ion-exchange mass spectrometry | STANFORD JUNIOR UNIVERSITY (US) | 2024-02-20 | — | — | US | claimed |
| US-20230204604-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING CHRONIC KIDNEY DISEASE | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2023-06-29 | — | — | US | claimed |
| WO-2022190030-A1 | A TOPICAL FORMULATION FOR THE TREATMENT OF SKIN DISEASES | AVACA PHARMA PRIVATE LIMITED (IN) | 2022-09-15 | — | — | WO | claimed |
| CN-114895018-A | Application of product for detecting metabolite level in serum in preparation of preparation for diagnosing various SLE patients and preparation | 中南大学湘雅二医院 | 2022-08-12 | — | — | CN | claimed |
| US-11215607-B2 | Biomarker for diagnosis of irritable bowel syndrome | ONO PHARMACEUTICAL CO., LTD. (JP) | 2022-01-04 | — | — | US | claimed |
| US-20190310269-A1 | SYSTEMS AND METHODS FOR MEASURING OBESITY USING METABOLOME ANALYSIS | HUMAN LONGEVITY, INC. | 2019-10-10 | — | — | US | claimed |
| WO-2017189528-A1 | CORROSION INHIBITOR COMPOSITIONS AND METHODS OF USING SAME | Ecolab USA, Inc. (US) | 2017-11-02 | — | — | WO | claimed |
| US-20170306504-A1 | CORROSION INHIBITOR COMPOSITIONS AND METHODS OF USING SAME | CHAMPIONX LLC | 2017-10-26 | — | — | US | claimed |
| US-20170059553-A1 | BIOMARKER FOR DIAGNOSIS OF IRRITABLE BOWEL SYNDROME | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-03-02 | — | — | US | claimed |
| US-8658351-B2 | Determining liver toxicity of an agent using metabolite biomarkers | METABOLON, INC. (US) | 2014-02-25 | — | — | US | claimed |
| US-8608922-B2 | Biosensor for continuous monitoring of metabolites and proteins and methods of manufacture thereof | THE UNIVERSITY OF CONNECTICUT (US) | 2013-12-17 | — | — | US | claimed |
| WO-2013070839-A1 | BIOMARKERS FOR BLADDER CANCER AND METHODS USING THE SAME | METABOLON, INC. (US) | 2013-05-16 | — | — | WO | claimed |
| WO-2012019295-A1 | BIOACTIVE COMPOUNDS IN CAMEL URINE AND MILK | ANTAKLY TONY (CA) | 2012-02-16 | — | — | WO | claimed |
| WO-2011051813-A1 | COMPOSITIONS AND METHODS FOR TREATING DERMATOLOGICAL CONDITIONS | PAUL HARBHAJAN S (US) | 2011-05-05 | — | — | WO | claimed |
| US-20110098229-A1 | COMPOSITIONS AND METHODS FOR TREATING DERMATOLOGICAL CONDITIONS | BIOMED RESEARCH & TECHNOLOGIES, INC. | 2011-04-28 | — | — | US | claimed |
| US-20100116691-A1 | BIOSENSOR FOR CONTINUOUS MONITORING OF METABOLITES AND PROTEINS AND METHODS OF MANUFACTURE THEREOF | UNIVERSITY OF CONNECTICUT (US) | 2010-05-13 | — | — | US | claimed |
| EP-1098630-A2 | COMPOSITION FOR ENHANCING EPIDERMAL LIPID PRODUCTION | Biomed Research and Technologies, Inc. (US) | 2001-05-16 | — | — | EP | claimed |
| US-6149924-A | FOR TOPICAL APPLICATION | BIOMED RESEARCH & TECHNOLOGIES, INC. (US) | 2000-11-21 | — | — | US | claimed |
| WO-2000004870-A2 | COMPOSITION FOR ENHANCING EPIDERMAL LIPID PRODUCTION | BIOMED RESEARCH AND TECHNOLOGIES, INC. (US) | 2000-02-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12584924-B2 | Compositions and methods for diagnosing and treating chronic kidney disease | GLS, AADAT, FGF23 | MME 169/4885ACE 1652/4885CPA1 126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.